CLCM
ESPR

Crawford Lake Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Crawford Lake Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$1.39M – 84
2017
Q2 		$1.39M Hold
30,000
– – 0.31% 78
2017
Q1 		$1.06M Buy
+30,000
New +$687K 0.42% 52

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Crawford Lake Capital Management's ESPR Position: Q3 2017 in Review

Crawford Lake Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2017, closing a stake of 32,295 shares — an estimated $1.5M sold.

Crawford Lake Capital Management first reported a position in ESPR in Q1 2017 and held it in 2 quarters. The position peaked at $3.3M in Q1 2017. 150 funds tracked by Wall St. Rank hold ESPR as of Q3 2017.

  • Crawford Lake Capital Management reported no remaining Esperion Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Crawford Lake Capital Management sold 32,295 Esperion Therapeutics shares in Q3 2017, an estimated $1.5M.
  • Crawford Lake Capital Management first reported a position in Esperion Therapeutics in Q1 2017 and held it in 2 quarters.
  • Crawford Lake Capital Management's Esperion Therapeutics position peaked at $3.3M in Q1 2017.
  • 150 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2017.

Based on Crawford Lake Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.